Envigo Corporate & Industry Overview. Rutgers University
|
|
|
- Jesse Norton
- 6 years ago
- Views:
Transcription
1 Envigo Corporate & Industry Overview Rutgers University Joseph Bedford, Ph.D. Corporate Vice President, Strategic Marketing November 15, 2016 envigo.com 1
2 Who we are Envigo is a global contract research products and services company serving pharmaceutical, chemical, crop protection, academic and government markets. envigo.com 2
3 Our brand promise Envigo focuses on what matters to you scientific and customer service excellence. We work closely with you to secure the potential of your research and products. We are dedicated to research that makes a difference in the lives of people all over the world. Together, we make the world a healthier and safer place to live. envigo.com 3
4 Global capacity, local presence 50+ locations Global availability of research models and CRO services 3 continents Our business spans North America, Europe and Asia 3,800+ employees Serving over 65 countries 150 years Combined industry experience envigo.com 4
5 Customers 53% 9% Envigo supports more than 5,000 customers across industry, academia and government each year + 19 of the top 20 global pharmaceutical companies More than 5,000 Customers per year + 15 of the top 20 crop protection and chemical companies + Virtual companies to multinationals + Academic and government biomedical researchers 38% Europe Asia North America envigo.com 5
6 Contract Research Services (CRS) envigo.com 6
7 CRS global footprint 7 locations Global availability research laboratory services 3 continents Extensive reach across North America, Europe and Asia 500 animal rooms Across our locations 1,600+ employees Serving over 65 countries 150 years Combined industry experience envigo.com 7
8 Services for the pharmaceutical industry Clinical Discovery services IND/ CTA enabling Proof of concept MAA/ BLA/ NDA Post-marketing Clinical study management and consultancy, bioanalytical support Regulatory affairs and consultancy, program management Nonclinical Investigative pharmacology Species selection Short-term safety studies Safety Pharmacology Biomarkers & Bioanalysis Sub-chronic safety studies Reproductive toxicology Biomarkers & Bioanalysis Chronic safety studies Reproductive toxicology Environmental risk assessment Biomarkers & Bioanalysis Formulation / indication changes Follow on products Investigational studies CMC GMP batch release and stability testing envigo.com 8
9 Contract Research Services Services General Toxicology all species Safety Pharmacology Cardiovascular Respiratory assessment Central nervous system Electrophysiology Speciality Toxicology Reproductive Inhalation Infusion Carcinogenicity Juvenile Neurotoxicity Special Pathology (e.g. crossreactivity) Genetic Toxicology Ames test Mouse lymphoma assay Chromosome aberration test In vitro micronucleus test In vivo micronucleus test Unscheduled DNA synthesis test (in vitro and in vivo) Comet assay (in vitro and in vivo) In Vivo Discovery Lead Optimization Pharmacology, Bioanalysis and Biomarker translational assessment Models in: Respiratory inflammation Gastrointestinal Anti-infective Cardiovascular Metabolism General ADME Biotransformation Metabolite Profiling In Vitro Metabolism Autoradiography Radiosynthesis Pharmacokinetics Analytical Support Bioanalysis Biologics and Biomarker Analysis Clinical Sample Analysis Dose Formulation Analysis Environmental Risk Assessment Terrestrial Ecotoxicology Aquatic Ecotoxicology Biodegradation Environmental Fate Animal Metabolism Regulatory and Clinical Consultancy (Pharma) CMC Testing Services Biopharmaceutical analysis including q-pcr Batch release and testing Stability testing Microbiology Stress testing Pharmacopeia testing envigo.com 9
10 CRS Pharmaceutical + Full range of services for pharmaceutical development + Animal health and medical device + Broad range of therapeutic areas + Experience working with startups through to the global top 20 envigo.com 10
11 Full service Services for the crop protection and chemical industries Agrochemicals Industrial chemicals Food Biocides products Regulatory strategy, scientific consultancy, managed programs Laboratory testing: Product chemistry, Genetic toxicology, Mammalian toxicology and oncogenicity, Ecotoxicology, Environmental fate/effects, Field trials/residues Dossier preparation, submission, post-submission envigo.com 11
12 CRS Crop Protection + Facilities across Europe, US, Japan, Korea and Israel + Full range of testing, regulatory and consultancy services for crop protection customers + Significant top 20 global customer base + Market-leading experience serving the crop protection industry globally envigo.com 12
13 CRS Chemicals + Facilities across Europe, US, Japan, Korea and Israel + Supporting our chemical customers with regulatory requirements (e.g.; REACH) + Global customer base + Market-leading experience serving chemical industry globally envigo.com 13
14 Examples of customer products we work on Pharmaceuticals Animal health products Polymers Coatings Airline fire extinguishers Fuel additives Textile treatments Environmental Personal care products Automotive products Oral care products Detergents Plant protection products Food additives and flavourings Pesticides Employee safety Medical devices Pigments, dyes and inks envigo.com 14
15 RMS Research animal models, services, diets, bedding and enrichment + Broad range of high-quality animal models available worldwide + Convenient, labor-saving services, including surgery, custom breeding, colony housing, and genetic and health monitoring + High-quality Teklad lab animal diets, bedding and environmental enrichment + Biologic products, including tissue, serum, and antibodies envigo.com 15
16 Research models Supporting a wide range of research areas + Aging + Behavior + Cardiovascular + Immunology + Metabolism + Oncology + Toxicology envigo.com 16
17 Research Models and Services Envigo production sites in North America, Europe, the Middle East and Asia North America Corporate HQ: Indianapolis, IN + Dublin, VA + Frederick, MD + Haslett, MI + Houston, TX + Indianapolis, IN + Livermore, CA + Madison, WI + Mexico City, Mexico Europe European Office: Venray, Netherlands + Blackthorn, UK + Bresso, Italy + Gannat, France + Horst, Netherlands + Loughborough, UK + Udine, Italy + Wyton, UK Middle East + Jerusalem, Israel + Rehovot, Israel + Yokneam, Israel India + Hyderabad, India envigo.com 17
18 Pharmaceuticals Industry Overview Key Facts + $1.05 Trillion in prescription drug sales + $160B spent on R&D worldwide + 810,000 US jobs, 3.4M indirectly + Over 150,000 R&D jobs + Over 7000 medicines in development + Progress in AIDS, Cancer, Hepatitis C, Vaccines, etc. envigo.com 18
19 Where will you spend your time? Aspects of drug development and commercialization envigo.com 19
20 Chemicals, Crop Protection Industry Overview Key Facts + $3.7 Trillion in sales worldwide + $50B spent on R&D worldwide + 4.5M job worldwide, 20M indirect + 820K jobs in US + Many thousands on market and 800 new products in development per year globally envigo.com 20
21 Where will you spend your time? Aspects of chemical products development and commercialization envigo.com 21
22 Envigo Brand Video envigo.com 22
23 Facilities Tour envigo.com 23
24 Thank you. Joseph Bedford, Ph.D. envigo.com 24
Optimisation de votre programme de développement
Optimisation de votre programme de développement Cedric Lamy, PhD. Cedric.lamy@crl.com Charles River Overview 65-year history: Founded in 1946, publicly traded (NYSE:CRL) Investment in skilled staff: ~7,500
BIOPHARMA SOLUTIONS TM Expedite Your Drug Development Program
BIOPHARMA SOLUTIONS TM Expedite Your Drug Program Maximize the Value of Your Asset The journey of drug development can be complex stressful. But it doesn t have to be that way. Join more than 600 biopharmaceutical
PRECLINICAL DRUG DISCOVERY AND DEVELOPMENT BIOBOOT CAMP 2016
PRECLINICAL DRUG DISCOVERY AND DEVELOPMENT BIOBOOT CAMP 2016 1 FROM DISCOVERY TO COMMERCIALIZATION At least 10 years on average Average spend of $1.4B Less than 12% of drugs entering Phase I are approved
A drug development crossroad lies ahead
G L O B A L C B O C O S T E F F E C T I V E B I O A N A L Y T I C A L H I G H Q U A L I T Y E A R L Y S T A G E C L I N I C A L T R A N S L A T I O N A L M E D I C I N E H I G H L Y C O M P E T E N T A
Guide to Services Our service map.
Guide to Services Our service map www.citoxlab.com France Full service nonclinical drug development LEADSCREEN TM : accelerated predictive toxicology screening Genetic toxicology Biomarkers and immunology
SPEED UP YOUR TIME TO MARKET
SPEED UP YOUR TIME TO MARKET #Pre-clinical #Biologics #Small molecules Welcome to Accelera. As a Contract Research Organization (CRO) serving since more than 30 years pharmaceutical and biotechnology companies
Drug Development Services
Drug Development Services Speaker Introduction Nik Burlew Vice President Regulatory and Strategic Development 25 Years in Pharma: Development, MFG and QA. Consulting for the last 13 years primarily to
Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research
Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research Drug Development Process by which new chemical entities
Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development
Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development Aernout van Haarst PhD Director, European Corporate Development Feb 2016 Industry Academic Collaboration
Harlan Laboratories. Contract Research Services
Harlan Laboratories Contract Research Services Table of Contents Overview 2 General Services General Toxicology 3 Reproductive Toxicology in Rats and Rabbits 3 Pathology and Histopathology 4 Genotoxicity
Baek, Kyung-min. Recombinant Protein Products Division. Ministry of Food and Drug Safety
Baek, Kyung-min Recombinant Protein Products Division Ministry of Food and Drug Safety About Ministry of Food and Drug Safety Regulation for Biosimilar Principle of Biosimilar Approach Status of Biosimilar
A full-service CRO with integrated early-stage capabilities
CHARLES RIVER TO ACQUIRE ARGENTA and BIOFOCUS A full-service CRO with integrated early-stage capabilities James C. Foster Chairman, President & CEO Thomas F. Ackerman Executive Vice President & CFO March
Preclinical Development Discovery to IND
Preclinical Development Discovery to IND Biobootcamp CBSA / Fitzsimons / FBBp / Holland & Hart Lauren C. Costantini, Ph.D. www.lccconsulting.net This Discussion Research and Development Product development
DMPK Overview. QPS is your Global Link to all your DMPK Sourcing Needs DMPK OVERVIEW CYP INDUCTION QWBA PROTEIN BINDING CYP INHIBITION
CYP INDUCTION QWBA PROTEIN BINDING CYP INHIBITION RADIOLABEL MASS BALANCE XENOGRAFT MODELS DMPK OVERVIEW ADME SUMMARY REPORT DMPK Overview QPS is your Global Link to all your DMPK Sourcing Needs Introduction
The Aptuit Center for Drug Discovery & Development Verona, Italy
The Aptuit Center for Drug Discovery & Development Verona, Italy 2 The Aptuit Center for Drug Discovery & Development Verona, Italy Aptuit in Verona: uncommon expertise, exceptional results A knowledgeable
ICH Topic E16 Genomic Biomarkers Related to Drug Response: Context, Structure and Format of Qualification Submissions. Step 3
European Medicines Agency June 2009 EMEA/CHMP/ICH/380636/2009 ICH Topic E16 Genomic Biomarkers Related to Drug Response: Context, Structure and Format of Qualification Submissions Step 3 NOTE FOR GUIDANCE
Paracelsus Course Objectives: Toxicology for the Laboratory Animal Scientist. General Toxicology Investigations. Reproductive Toxicology
Toxicology for the Laboratory Animal Scientist CL Davis Foundation Topics in Laboratory Animal Medicine May 7, 2009 Angela King-Herbert, DVM, DACLAM NTP/NIEHS RTP NC Course Objectives: Define terms used
Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y. Report Price Publication date
F o r a c l e a r e r m a r k e t p e r s p e c t i v e Early Stage Drug Safety Strategies & Risk Management Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y Report
KFDA Regulatory Framework on Biopharmaceuticals - Focus on Biosimilar
KFDA Regulatory Framework on Biopharmaceuticals - Focus on Biosimilar Kyung-Min Baek, Ph.D. Recombinant Protein Products Division Korea Food and Drug Administration(KFDA) Biopharmaceuticals A biopharmaceutical
Introduction to CMC Regulatory Affairs
Introduction to CMC Regulatory Affairs Bharathi Mamidipudi Regulatory Affairs Consultant II Syner-G Pharma Consulting, LLC Northeastern University, Boston November 10, 2016 My Background Experience ~4
Oncology Biopharmaceuticals and Preclinical Development: Evolving Regulatory Challenges
The content of this presentation reflects the opinion of the speaker and does not necessarily represent the official position of CDER Oncology Biopharmaceuticals and Preclinical Development: Evolving Regulatory
A Global CRO STRONGER TOGETHER
A Global CRO STRONGER TOGETHER About us Unique Service Offering the first agrochemical CRO to offer a truly global service Part of the Eurofins Scientific Group of companies, Eurofins Agroscience Services
Structure and content of an IMPD. What is required for first into man trial?
What is required for first into man? The EU IMPD Thomas Sudhop, MD Scope Structure and content of an IMPD What is required for first into man trial? Only for IMPs that do not have a marketing authorisation
BSc BIOMEDICAL SCIENCE
Overview College of Science Biomedical Science Core March 2017 (1) BSc BIOMEDICAL SCIENCE Biomedical Science Degree 2015 1 College of Science, NUI Galway Fullscreen Next page Overview [60 credits] [60
ESTIMATE THE IMPACT OF TIME SAVINGS ON YOUR DRUG DEVELOPMENT PROGRAM, ASSET VALUE AND FINANCIAL COMPANY PERFORMANCE
ESTIMATE THE IMPACT OF TIME SAVINGS ON YOUR DRUG DEVELOPMENT PROGRAM, ASSET VALUE AND FINANCIAL COMPANY PERFORMANCE An Economic Comparison of Programmatic and Transactional Development Models PETER SAUSEN,
The Emerging Technology Program: FDA s Perspective
The Emerging Technology Program: FDA s Perspective Mohan Sapru, M.S., Ph.D. Member Emerging Technology Team (ETT) CMC Lead Application Technical Lead Office of New Drug Products Office of Pharmaceutical
Non-clinical Assessment Requirements
Non-clinical Assessment Requirements Presented by: Maria Nieto-Gutierrez Safety and Efficacy of Medicines/Human Medicines Development and Evaluation An agency of the European Union Contents: Relevance
Non-clinical documentation Overview of Requirements
3 rd EMEA-. Non-clinical Aspects Non-clinical documentation Overview of Requirements EMEA Pre-Authorisation Human Unit 3 rd EMEA-. Non-clinical Aspects Outline Overview of Legal and Regulatory requirements
Global Development Challenges: Classical and Advanced Therapy Medicinal products
Global Development Challenges: Classical and Advanced Therapy Medicinal products Beatriz Silva Lima imed, Lisbon University and Infarmed,, Portugal CHMP, CAT, SAWP Member and SWP Chair NONCLINICAL STUDIES
The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Catalog Addendum
The University of Texas MD Anderson Cancer Center UTHealth 2016-2018 Catalog Addendum GSBS 2016-18 Catalog Addendum Table of Contents School Name Change... 1 Areas of Research Concentration Changes...
US FDA: CMC Issues for INDs
ISBTC Global Regulatory Summit October 29, 2008 US FDA: CMC Issues for INDs Keith Wonnacott, Ph.D. keith.wonnacott@fda.hhs.gov US Food and Drug Administration Center for Biologics Evaluation and Research
S9 Implementation Working Group ICH S9 Guideline: Nonclinical Evaluation for Anticancer Pharmaceuticals Questions and Answers
S9 Implementation Working Group ICH S9 Guideline: Nonclinical Evaluation for Anticancer Pharmaceuticals Questions and Answers Current version dated 8 June 2016 International Council for Harmonisation of
Regulatory Challenges of Global Drug Development in Oncology. Jurij Petrin, M.D. Princeton, NJ
Regulatory Challenges of Global Drug Development in Oncology Jurij Petrin, M.D. Princeton, NJ Topics General global R&D issues Regulatory issues with global oncology drug development US FDA initiatives
Global Clinical Trials in Korea
Global Clinical Trials in Korea In-Sook Park Department of Drug Evaluation Korea Food & Drug Administration Contents Regulatory changes relevant to Clinical Trials in Korea Current Status of Clinical Trials
CTA/NDA Regulatory Landscape in China. Jack Xie, PhD, DABT SOT 2016
CTA/NDA Regulatory Landscape in China Jack Xie, PhD, DABT SOT 2016 Disclaimer The content of the following presentation represents solely author s view and may not reflect any position of Roche or China
MSCI 689: Career Development for the Biomedical PhD Scientist Introduction to Medical Writing and Drug Development
MSCI 689: Career Development for the Biomedical PhD Scientist Introduction to Medical Writing and Drug Development Danielle K Lewis, PhD April 28, 2017 One-Stop Shop Regulatory Submissions Regulatory Operations
BSc Biomedical Science Degree
BSc Biomedical Science Degree Overview...2 BSc Biomedical Science...3 BSc Biomedical Science Pathway...4 BSc Biomedical Science Biochemistry Pathway...5 BSc Biomedical Science Pathway...6 BSc Biomedical
Our Business. in vitro / in vivo. in vitro / in vivo ADME. in vitro / in vivo. Toxicology. Cell Battery V79. Analytical Services. Service.
GenPharmTox is one of the few CROs who can guarantee the success of our project within the given time framework and on the terms agreed. Dr. Michael Runkel, Apogepha GmbH 3 3 In vitro 3.1. Phototoxicity
The Right Molecules. Designed. Delivered.
The Right Molecules. Designed. Delivered. 400+ Worldwide Clients 80+ Medicinal Chemistry Programs 20+ Preclinical Candidates Delivered Since 2008 10+ In IND Stage 5 Entered Phase I Clinical Trials 2 Entered
Testing Methods and Directives
EUROPEAN COMMISSION DIRECTORATE GENERAL - JRC JOINT RESEARCH CENTRE Institute for Health and Consumer Protection Unit: Toxicology and Chemical Substances European Chemicals Bureau D:\My Documents\JR\Tables\OFFJOUR\Listofoj.doc
COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BMWP/42832/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR
The TetraQ Difference. Quality Preclinical Drug Development Solutions. Provide advice and tailored solutions, not just a menu of choices
A leading Australian contract research organisation (CRO) providing integrated preclinical drug development services to the biotech and pharmaceutical industries The TetraQ Difference Located at The University
Early Phase Education WHITEPAPER. Three major items to consider when moving from preclinical to clinical development
Early Phase Education WHITEPAPER Three major items to consider when moving from preclinical to clinical development Three major items to consider when moving from preclinical to clinical development Dr.
COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE NON-CLINICAL DEVELOPMENT OF FIXED COMBINATIONS OF MEDICINAL PRODUCTS
European Medicines Agency London, 24 January 2008 Doc. Ref. EMEA/CHMP/SWP/258498/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE NON-CLINICAL DEVELOPMENT OF FIXED COMBINATIONS
TECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT
Specialist in tissue analysis by Histology, Immunohistochemistry and In Situ Hybridization TECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT CONTENTS Histalim: who we are Our areas of expertise
Konica Minolta to Acquire Invicro (US)
Konica Minolta to Acquire Invicro (US) Acceleration of expansion of precision medicine business Offering new value for drug discovery and development in immuno-oncology and neurodegenerative disease September
Celerion s Symposia Series: Bridging the Gap from Phase I to Proof-of-Concept. San Francisco, CA Tue 8 th, Apr 2014
Celerion s Symposia Series: Bridging the Gap from Phase I to Proof-of-Concept San Francisco, CA Tue 8 th, Apr 2014 Mind the Gap: Elements of a Bridging Strategy J. Fred Pritchard, Ph.D. Vice President,
2017 Call for Proposals EDCTP-TDR Clinical Research and Development Fellowships
2017 Call for Proposals EDCTP-TDR Clinical Research and Development Fellowships Call Identifier: TMA2017IF The purpose of this Call for Proposals is to provide funding towards actions that aim to support
OSWG s Role in Shaping the Regulatory Development of Oligos - A Potential Model for Moving Forward -
OSWG s Role in Shaping the Regulatory Development of Oligos - A Potential Model for Moving Forward - David H. Schubert VP, Regulatory and Quality Outline What? Background and History Who? How? OSWG Committees
CRO partner in Rx/CDx Co-Development
CRO partner in Rx/CDx Co-Development DEDICATED DIALOGUE A sponsored roundtable discussion published in Pharmaceutical Executive Two Covance executives discuss a CRO s role in supporting Companion Diagnostics
**MATERIAL SAFETY DATA SHEET**
Date Issued: August 19, 2009 Version: 5.0 Supersedes: August 8, 2006 Page 1 of 5 Section 1 Product and Company Identification Product Name: Herceptin Chemical Name: Anti-p185 HER2 Chemical Family: High
Overview of Biologics Testing and Evaluation: Regulatory Requirements and Expectations. Audrey Chang, PhD, Senior Director Development Services
Overview of Biologics Testing and Evaluation: Regulatory Requirements and Expectations Audrey Chang, PhD, Senior Director Development Services Definition of Biologics: PHS Act, section 351 Virus, therapeutic
Pharmacology. Chatchai Chinpaisal, Ph.D. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Silpakorn University.
Pharmacology Chatchai Chinpaisal, Ph.D. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Silpakorn University. 1 PHARMACODYNAMIC STUDIES A. Primary pharmacodynamics primary action in target
SHORT COURSE. Practical Considerations for Biomarker Bioanalysis: Scientific and Regulatory Perspective SUNDAY, SEPTEMBER 17
SHORT COURSE SUNDAY, SEPTEMBER 17 OMNI PROVIDENCE HOTEL PROVIDENCE, RI Practical Considerations for Biomarker Bioanalysis: Scientific and Regulatory Perspective SPONSORED BY: Organized by: www.bostonsociety.org
The room was more than 3/4 full with greater than 150 people in attendance.
Summary The room was more than 3/4 full with greater than 150 people in attendance. The questions were well distributed across all four panelists. All the Panelists were very interactive and were able
Program of study. pharmacy. 1st year
II I Program of study pharmacy 1st year Anatomy 15-15 GC Biophysics 15 15 - E Biology and Genetics 60 15 15 E 4 Botany 90 45 15 E 7 Analytical I 4 1 - E General and Inorganic 105 45 E 7 Latin Course -
GENE EXPRESSION REAGENTS MARKETS (SAMPLE COPY, NOT FOR RESALE)
TriMark Publications April 2007 Volume: TMRGER07-0401 GENE EXPRESSION REAGENTS MARKETS (SAMPLE COPY, NOT FOR RESALE) Trends, Industry Participants, Product Overviews and Market Drivers TABLE OF CONTENTS
Recommendation on elements required to support the medical plausibility and the assumption of significant benefit for an orphan designation
2 March 2010 EMA/COMP/15893/2009 Final Committee for Orphan Medicinal Products (COMP) Recommendation on elements required to support the medical plausibility and the assumption of significant benefit for
Formulation Development of New Chemical Entities (NCEs) Dr. Mariella Artusi Pharmaceutical Development Dept. Monza
Formulation Development of New Chemical Entities (NCEs) Dr. Mariella Artusi Pharmaceutical Development Dept. Monza HorizonChem 2018, March, 6th 2018 1 Content Rottapharm Biotech : Company Overview Formulation
LYSARC, ACADEMIC PARTNER OF LYMPHOMA CLINICAL RESEARCH. EN
LYSARC, ACADEMIC PARTNER OF LYMPHOMA CLINICAL RESEARCH EN www.lysarc.org THE LARGEST EUROPEAN ACADEMIC ORGANIZATION DEVOTED TO CLINICAL RESEARCH OPERATIONS IN THE LYMPHOMA FIELD Lymphoma is the 6th most
Paradigm Shift in Comparability Assessment:
Paradigm Shift in Comparability Assessment: How Quality by Design (QbD) and Process Analytical Technology (PAT) can improve Structure-Activity Relationship (SAR) evaluation and its relevance to comparability
WuXi PharmaTech: Building an Open-Access Capability and Technology Platform. Jefferies Healthcare Conference November 2014
WuXi PharmaTech: Building an Open-Access Capability and Technology Platform Jefferies Healthcare Conference November 2014 Cautionary Note Regarding Forward-Looking Statements This presentation contains
The Innovative Medicines Initiative: Building new models of collaborative research across Europe
The Innovative Medicines Initiative: Building new models of collaborative research across Europe Elisabetta Vaudano IMI, Belgium www.imi.europa.eu What is IMI? An European Public-Private Partnership Focused
Center for Drug Evaluation and Research. CDER Small Business and Industry Assistance. (CDER SBIA) and New Drug Review.
Center for Drug Evaluation and Research Small Business and Industry Assistance (CDER SBIA) and New Drug Review LT Renu Lal, Pharm.D. CDER Small Business and Industry Assistance Division of Drug Information
Doctor of Pharmacy Course Descriptions
Doctor of Pharmacy Course Descriptions Required Courses Pharmacy Practicum II (7002) Second practicum with direct instruction by an experienced preceptor to increase the student's awareness of the pharmacist's
Regulatory Affairs, Compliance Assurance, Quality Systems, Remediation Strategy and Support, and Strategic Consulting Services
Regulatory Affairs, Compliance Assurance, Quality Systems, Remediation Strategy and Support, and Strategic Consulting Services At Regulatory Compliance Associates Inc. (RCA) we understand the complexities
4th ANTWERP BIOPHARM DAY SAFETY & EFFICACY CLINICAL TRIALS SOLUTIONS DATE: OCTOBER 29, 2015
4th ANTWERP BIOPHARM DAY SAFETY & EFFICACY CLINICAL TRIALS SOLUTIONS DATE: OCTOBER 29, 2015 VENUE: LINDNER HOTEL LANGE KIEVITSTRAAT 125 BE-2018 ANTWERP, BELGIUM 2 Join the 4 th one-day seminar to discuss
The Role of a Notified Body in Defining Risk Assessment for a Recombinant Protein Used in a Medical Device Case Study
The Role of a Notified Body in Defining Risk Assessment for a Recombinant Protein Used in a Medical Device Case Study CMC Strategy Forum Europe 2015 Update on Medical Device/Combination Products Karin
COPYRIGHTED MATERIAL. IN THISchapter, we first give definitions of the assay and the bioassay. INTRODUCTION TO ASSAY DEVELOPMENT
CHAPTER1 INTRODUCTION TO ASSAY DEVELOPMENT IN THISchapter, we first give definitions of the assay and the bioassay. Drug discovery and development processes are then reviewed to show the role bioassay
Developing innovative new medicines for acute and chronic neurological and psychiatric conditions Larry Glass, CEO
Developing innovative new medicines for acute and chronic neurological and psychiatric conditions Larry Glass, CEO (lglass@neurenpharma.com) Neuren Pharmaceuticals Created to commercialize University of
Guidelines and criteria for seeking approval to conduct clinical trials in Ayurveda, Siddha and Unani system.
Guidelines and criteria for seeking approval to conduct clinical trials in Ayurveda, Siddha and Unani system. Application for seeking approval of the Central Government for conduct of clinical trial in
Emerging Trends in Regulatory Outsourcing WHITE PAPER.
WHITE PAPER www.makrocare.com/consulting You are not alone in the quest for bringing your products to market and improve the quality of the life for millions! MakroCare brings you the insight on how a
CRYSTAL CITY V REDUX: GUIDANCE FOR INDUSTRY BIOANALYTICAL METHOD VALIDATION DRAFT GUIDANCE (2013) VI. ADDITIONAL ISSUES
CRYSTAL CITY V REDUX: GUIDANCE FOR INDUSTRY BIOANALYTICAL METHOD VALIDATION DRAFT GUIDANCE (2013) VI. ADDITIONAL ISSUES DELAWARE VALLEY DRUG METABOLISM DISCUSSION GROUP STEVE PICCOLI, BMS RAND JENKINS,
Roche, Roche Molecular Diagnostics and more
, Molecular and more [Monte Wetzel, PhD] Patients have questions. We provide answers. Group Clear focus on Healthcare Innovation with two strong pillars Pharma Pharma Genentech Chugai Molecular Professional
School of Pharmacy TEMPLE UNIVERSITY
School of Pharmacy TEMPLE UNIVERSITY Regulatory Affairs and Quality Assurance Graduate Program Te mple Unive rsity School of Pharmacy Re gulatory Affairs and Quality Assurance Graduate Program 4 25 Comme
Corporate Presentation & Offer for SAP ATTP December 2015
Corporate Presentation & Offer for SAP ATTP December 2015 Page : 1 Page : 2 Content Our Vision Our Company Business Challenges SAP Advanced Track and Trace for Pharmaceuticals (ATTP) Our Offer Our Vision
Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing
Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing Overview Serving biotech and pharma community since 1998 Proven track record of advancing small molecules from
Life SCIENCE GR ADUATE SCHOOL OF
GR ADUATE SCHOOL OF Life SCIENCE Transdisciplinary Life Science Course Biosystems Science Course Biomedical and Pharmaceutical Science Course Division of Clinical Pharmacy Message from the Dean Masakane
DISCOVER OUR SEGMENT REGULATORY SCIENCE
DISCOVER OUR SEGMENT REGULATORY SCIENCE Our focus In the demanding regulatory environment of the EU, expert knowledge is essential to gaining approval for substances and products. That is why the scientific
Adding value to Indigenous Knowledge through Scientific Innovation
THE WORLD BANK Adding value to Indigenous Knowledge through Scientific Innovation INTERNATIONAL WORKSHOP ON INDIGENOUS KNOWLEDGE Benoni, South Africa 9-11 February 2005 Marthinus Horak Programme CSIR Bio/Chemtek
REIMAGINING DRUG DEVELOPMENT:
Biology Reconstructed REIMAGINING DRUG DEVELOPMENT: Accurate Disease Modeling To Drive Successful Therapies Julia Kirshner, CEO julia@zpredicta.com 1 SUCCESS RATES OF DRUG DEVELOPMENT ARE LOW, " PARTICULARLY
HARMONISING ENVIRONMENTAL RISK ASSESSMENTS OF PESTICIDES
HARMONISING ENVIRONMENTAL RISK ASSESSMENTS OF PESTICIDES OECD DEVELOPMENT OF TEST GUIDELINES AND METHODOLOGIES EFSA Scientific Conference on ERA of pesticides Parma, 15-16 November 2016 OECD Secretariat
Novartis Business Services HR University Relations. Clinical Sciences and Innovation. Postgraduate Program
Novartis Business Services HR University Relations Clinical Sciences and Innovation Postgraduate Program 2 CLINICAL SCIENCES AND INNOVATION CLINICAL SCIENCES AND INNOVATION 3 The CS&I Postgraduate Program
Technology Development Funding Program Round 3
Technology Development Funding Program Round 3 CWRU January 26, 2015 1 Program Overview NIH Center for Accelerated Innovations (NCAI) at Cleveland Clinic Mission to improve translation of basic science
STARTING STRONGER IN PHASE I THROUGH IIA
PAREXEL CLINICAL RESEARCH SERVICES: EARLY PHASE STARTING STRONGER IN PHASE I THROUGH IIA Adding value from first-in-human through proof-of-concept YOUR JOURNEY. OUR MISSION. Achieve success through early
Guideline on repeated dose toxicity
18 March 2010 CPMP/SWP/1042/99 Rev 1 Committee for Human Medicinal Products (CHMP) Guideline on repeated dose toxicity Draft Agreed by Safety Working Party May - December 2007 Adoption by CHMP for release
The In Vitro Diagnostic CRO
The In Vitro Diagnostic CRO Choose Beaufort Because of Our People, Processes and Proven Experience The value of expertise cannot be overstated, especially when it comes to streamlining complicated in vitro
The largest network of harmonized bio/ pharmaceutical GMP product testing labs worldwide, Eurofins BioPharma Product Testing enables companies to
The largest network of harmonized bio/ pharmaceutical GMP product testing labs worldwide, Eurofins BioPharma Product Testing enables companies to advance candidates from development through commercialization
QUESTIONS AND ANSWERS TO ICH S3A: NOTE FOR GUIDANCE ON TOXICOKINETICS: THE ASSESSMENT OF SYSTEMIC EXPOSURE IN TOXICITY STUDIES FOCUS ON MICROSAMPLING
INTERNATIONAL COUNCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED GUIDELINE QUESTIONS AND ANSWERS TO ICH S3A: NOTE FOR GUIDANCE ON TOXICOKINETICS: THE ASSESSMENT
Dr Amy Prosser Careers in Research: Industry
www.rsb.org.uk Dr Amy Prosser Careers in Research: Industry @RoyalSocBio #BiologyWeek #RSBcareersDay Careers in Research: Working in the Pharma Industry Dr Amy Prosser My Career History 2011 Completed
National Foundation for Women Legislators Annual Meeting September 12, 2015 Tara Ryan Vice President, State Government Advocacy
From Hope to Cures: The Value of Biopharmaceutical Innovation National Foundation for Women Legislators Annual Meeting September 12, 2015 Tara Ryan Vice President, State Government Advocacy HIV/AIDS: Then
Skills Required by Pharmacologists and Physiologists in Today s Pharmaceu:cal Industry
Skills Required by Pharmacologists and Physiologists in Today s Pharmaceu:cal Industry Iok- Hou Pang, PhD Pharmaceutical Sciences!! University of North Texas Health Science Center! Outline of Presenta:on
ATIP Avenir Program 2018 Young group leader
ATIP Avenir Program 2018 Young group leader Important dates - October 17th (4 pm) 2017 : opening of the registrations online - November 23 th 2017: deadline for the online submission, the mailing of the
European Regenerative Medicine Firms & Their Strategic Approaches. Michael Morrison University of York
European Regenerative Medicine Firms & Their Strategic Approaches Michael Morrison University of York OVERVIEW Creating the European RM Universe of firms Characterizing the European RM Universe Strategic
ADVANCING SCIENTIFIC INNOVATION Together, the possibilities are endless.
ADVANCING SCIENTIFIC INNOVATION Together, the possibilities are endless. COMMUNICATE INNOVATE EXPLORE COLLABORATE PARTNERSHIPS THAT BENEFIT YOU, US, AND ALL OF MANKIND Since Eli Lilly and Company was founded
ICH Guideline S3A: Note for guidance on toxicokinetics: the assessment of systemic exposure in toxicity studies - questions and answers
14 December EMA/CHMP/ICH/320985/2016 Committee for Medicinal Products for Human Use ICH Guideline S3A: Note for guidance on toxicokinetics: the assessment of systemic exposure in toxicity studies - questions
BIOMEDICAL SCIENCES. Graduate Programs. Biomedical Sciences 1
Biomedical Sciences 1 BIOMEDICAL SCIENCES Professional Program of Study For professional curriculum in veterinary medicine leading to the degree doctor of veterinary medicine, see Veterinary Medicine,